AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
Status:
COMPLETED
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese patients with hyperphosphatemia.